MNKD Mannkind Corp

Price (delayed)

$5.85

Market cap

$1.59B

P/E Ratio

146.25

Dividend/share

N/A

EPS

$0.04

Enterprise value

$1.91B

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its ...

Highlights

Mannkind's EPS has soared by 200% from the previous quarter and by 114% YoY

Mannkind's net income has soared by 171% from the previous quarter and by 112% YoY

The company's debt rose by 33% YoY

Sector: Healthcare

Industry: Biotechnology

Website: http://www.mannkindcorp.com/

Peers: HALO NKTR LLY PFE

Key stats

What are the main financial stats of MNKD

Market

Shares outstanding

272.32M

Market cap

$1.59B

Enterprise value

$1.91B

Valuations

Price to earnings (P/E)

146.25

Price to book (P/B)

N/A

Price to sales (P/S)

7.04

EV/EBIT

48.3

EV/EBITDA

41.82

EV/Sales

8.5

Earnings

Revenue

$224.6M

EBIT

$39.53M

EBITDA

$45.65M

Free cash flow

$3.1M

Per share

EPS

$0.04

Free cash flow per share

$0.01

Book value per share

-$0.85

Revenue per share

$0.83

TBVPS

$1.77

Balance sheet

Total assets

$480.88M

Total liabilities

$710.85M

Debt

$509.29M

Equity

-$229.97M

Working capital

$283.21M

Liquidity

Debt to equity

-2.21

Current ratio

3.84

Quick ratio

3.21

Net debt/EBITDA

6.92

Margins

EBITDA margin

20.3%

Gross margin

71%

Net margin

3.8%

Operating margin

13.8%

Efficiency

Return on assets

2.1%

Return on equity

N/A

Return on invested capital

6.7%

Return on capital employed

10.4%

Return on sales

17.6%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

MNKD stock price

How has the Mannkind stock price performed over time

Intraday

0.86%

1 week

2.45%

1 month

12.72%

1 year

32.65%

YTD

60.71%

QTD

12.07%

Financial performance

How have Mannkind's revenue and profit performed over time

Revenue

$224.6M

Gross profit

$159.44M

Operating income

$30.96M

Net income

$8.49M

Gross margin

71%

Net margin

3.8%

MNKD's operating income has soared by 192% QoQ and by 161% YoY

Mannkind's net income has soared by 171% from the previous quarter and by 112% YoY

The company's net margin has surged by 163% QoQ and by 107% YoY

MNKD's operating margin has surged by 160% since the previous quarter and by 135% year-on-year

Growth

What is Mannkind's growth rate over time

Valuation

What is Mannkind stock price valuation

MNKD P/E details

P/E

146.25

P/B

N/A

P/S

7.04

EV/EBIT

48.3

EV/EBITDA

41.82

EV/Sales

8.5

Mannkind's EPS has soared by 200% from the previous quarter and by 114% YoY

The equity has increased by 10% year-on-year and by 7% since the previous quarter

The revenue has soared by 75% YoY and by 13% from the previous quarter

The P/S is 26% lower than the 5-year quarterly average of 9.5 but 19% higher than the last 4 quarters average of 5.9

Efficiency

How efficient is Mannkind business performance

The company's return on invested capital has surged by 179% YoY and by 148% QoQ

The ROA has soared by 162% QoQ and by 109% YoY

Mannkind's ROS has soared by 149% YoY and by 138% from the previous quarter

Dividends

What is MNKD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for MNKD.

Financial health

How did Mannkind financials performed over time

The company's total assets is 32% lower than its total liabilities

The company's total assets has surged by 61% YoY

The company's current ratio rose by 41% YoY and by 7% QoQ

The debt to equity is down by 47% year-on-year and by 6% since the previous quarter

The company's debt rose by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.